AUSTIN BROWN to Adolescent
This is a "connection" page, showing publications AUSTIN BROWN has written about Adolescent.
Connection Strength
0.639
-
Prediction of methotrexate neurotoxicity using clinical, sociodemographic, and area-based information in children with acute lymphoblastic leukemia. Oncologist. 2025 Jun 04; 30(6).
Score: 0.065
-
Evaluation of methotrexate Pharmacogenomic variation to predict acute neurotoxicity in children with acute lymphoblastic leukemia. Pharmacotherapy. 2025 Jan; 45(1):4-11.
Score: 0.063
-
Episodes of acute methotrexate-related neurotoxicity linked to compromised long-term neurocognitive function. Pediatr Blood Cancer. 2024 Sep; 71(9):e31169.
Score: 0.061
-
Comparison of the blood, bone marrow, and cerebrospinal fluid metabolomes in children with b-cell acute lymphoblastic leukemia. Sci Rep. 2021 10 04; 11(1):19613.
Score: 0.051
-
Prospective patient-reported symptom profiles associated with pediatric acute lymphoblastic leukemia relapse. Support Care Cancer. 2021 May; 29(5):2455-2464.
Score: 0.047
-
Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A population-based assessment. Cancer. 2019 10 15; 125(20):3623-3630.
Score: 0.043
-
Pilot study of DNA methylation-derived neutrophil-to-lymphocyte ratio and survival in pediatric medulloblastoma. Cancer Epidemiol. 2019 04; 59:71-74.
Score: 0.042
-
DNA methylation of a novel PAK4 locus influences ototoxicity susceptibility following cisplatin and radiation therapy for pediatric embryonal tumors. Neuro Oncol. 2017 Oct 01; 19(10):1372-1379.
Score: 0.038
-
Prevalence and Predictors of Overweight and Obesity Among a Multiethnic Population of Pediatric Acute Lymphoblastic Leukemia Survivors: A Cross-Sectional Assessment. J Pediatr Hematol Oncol. 2016 08; 38(6):429-36.
Score: 0.035
-
SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma. Cancer Med. 2015 Nov; 4(11):1679-86.
Score: 0.033
-
Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy. J Clin Oncol. 2025 Jul; 43(19):2173-2183.
Score: 0.016
-
What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High-Dose Methotrexate Use in Pediatric Malignancies. Pediatr Blood Cancer. 2025 Jul; 72(7):e31744.
Score: 0.016
-
Metabolic syndrome in childhood, adolescent, and young adult cancer survivors: recommendations for surveillance from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Eur J Endocrinol. 2025 Mar 27; 192(4):S27-S40.
Score: 0.016
-
Delayed excretion of high-dose methotrexate in pediatric acute leukemia correlates with laxative and constipation management. Pediatr Blood Cancer. 2025 Jan; 72(1):e31377.
Score: 0.016
-
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma. Neuro Oncol. 2024 Oct 03; 26(10):1912-1920.
Score: 0.016
-
Longitudinal investigation of suicidal ideation and associated factors during pediatric acute lymphoblastic leukemia chemotherapy. Psychooncology. 2022 10; 31(10):1782-1789.
Score: 0.013
-
Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2022 12; 63(12):2948-2954.
Score: 0.013
-
Early evidence of pulmonary dysfunction in survivors of childhood Hodgkin lymphoma. Leuk Lymphoma. 2020 10; 61(10):2419-2427.
Score: 0.012
-
Effect of sensorineural hearing loss on neurocognitive and adaptive functioning in survivors of pediatric embryonal brain tumor. J Neurooncol. 2020 Jan; 146(1):147-156.
Score: 0.011
-
Adaptive functioning in pediatric brain tumor survivors: An examination of ethnicity and socioeconomic status. Pediatr Blood Cancer. 2019 09; 66(9):e27800.
Score: 0.011
-
DNA methylation and obesity in survivors of pediatric acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Genes Chromosomes Cancer. 2019 01; 58(1):52-59.
Score: 0.010
-
Exploratory analysis of ERCC2 DNA methylation in survival among pediatric medulloblastoma patients. Cancer Epidemiol. 2016 10; 44:161-166.
Score: 0.009